Welcome to HMP MAI’s 2023 research year!
We want to give you a look at some of the topics we’re planning to explore this year, as we enter yet another period of rapid change, upheaval, and uncertainty in 2023-2025.
Here’s our take on three well-established trends we expect to continue. These changes require taking a hard look at your health care provider and payer engagement strategies for 2023 and 2024.
Oncologists continue to consolidate into larger groups and networks. We estimate that approximately 55% of medical oncologists currently work with IDNs, while another 20-21% are employed within US Oncology, OneOncology, AON, or a sophisticated independent group tied to QCCA or NCCA. We estimate that just 24% of oncologists still practice in the traditional small group segment with little or no internal medical management infrastructure.
*Estimates based on HMP MAI analysis of Magellan 2018 report, individual community oncology group data, ASCO practice survey
CMS and commercial payers seek to reduce prices for all goods and services delivered to cancer patients
Vertical payers are growing their roles in delivering and managing care, but strategies vary substantially.
Check back in a few weeks for our next blog post that looks at several interesting wild cards for the 2023-2025 time period!
All the best...
-- HMP Market Access Insights Team
Welcome to the August 2023 edition of our Monthly Insight Series. This month we take a deeper look into independent community oncology practices’ evolving interest in joining oncology network aggregators.
Taylor CrutisonCMMI has launched its new oncology pilot, the Enhancing Oncology Model, sparking questions about its new features vs the Oncology Care Model, the benefits and concerns for participating practices, and CMMI’s ability to successfully implement the program.
Taylor CrutisonWelcome to the July 2023 edition of our Monthly Insights Series. This month we want to share some more thoughts on opportunities for manufacturer engagement with IDN stakeholders—the IDN pharmacy/pharmacists, in particular.
Cindy Chen